Skip header and navigation

1 records – page 1 of 1.

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

https://arctichealth.org/en/permalink/ahliterature150732
Source
Clin Pharmacol Ther. 2009 Aug;86(2):197-203
Publication Type
Article
Date
Aug-2009
Author
J E Keskitalo
O. Zolk
M F Fromm
K J Kurkinen
P J Neuvonen
M. Niemi
Author Affiliation
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Source
Clin Pharmacol Ther. 2009 Aug;86(2):197-203
Date
Aug-2009
Language
English
Publication Type
Article
Keywords
ATP-Binding Cassette Transporters - genetics
Adult
Anticholesteremic Agents - pharmacokinetics
Area Under Curve
Cross-Over Studies
Drug Resistance, Multiple
European Continental Ancestry Group - genetics
Female
Finland
Fluorobenzenes - administration & dosage - blood - pharmacokinetics - urine
Genotype
Heptanoic Acids - administration & dosage - blood - pharmacokinetics - urine
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics
Linear Models
Male
Neoplasm Proteins - genetics
Polymorphism, Single Nucleotide
Pyrimidines - administration & dosage - blood - pharmacokinetics - urine
Pyrroles - administration & dosage - blood - pharmacokinetics - urine
Reference Values
Sulfonamides - administration & dosage - blood - pharmacokinetics - urine
Abstract
The ABCG2 c.421C>A single-nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic crossover study involving the administration of 20 mg atorvastatin and rosuvastatin. The frequency of the c.421A variant allele was 9.5% (95% confidence interval 8.1-11.3%). Subjects with the c.421AA genotype (n = 4) had a 72% larger mean area under the plasma atorvastatin concentration-time curve from time 0 to infinity (AUC(0-infinity)) than individuals with the c.421CC genotype had (n = 16; P = 0.049). In participants with the c.421AA genotype, the rosuvastatin AUC(0-infinity) was 100% greater than in those with c.421CA (n = 12) and 144% greater than in those with the c.421CC genotype. Also, those with the c.421AA genotype showed peak plasma rosuvastatin concentrations 108% higher than those in the c.421CA genotype group and 131% higher than those in the c.421CC genotype group (P
PubMed ID
19474787 View in PubMed
Less detail